{
  "trial_id": "NCT01681433",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "study",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Histological or cytological diagnosis of adenocarcinoma of the prostate",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Evaluations at 4 week-intervals. Disease assessments required at the milestone Day 60 assessment (expected to occur after 8 weeks of treatment and prior to Day 1, Week 9) and at 16, 24, 32, 40, and 48 weeks (if applicable) or until documented disease progression.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "notes": "Patient has symptoms consistent with a serious illness, but no underlying disease is mentioned. He is not on any medications.",
  "_meta": {
    "topic_id": "32",
    "trial_id": "NCT01681433",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}